text:
Click to See All Seasons
Season 1 Season 2 Season 3 Season 4 Season 5
Episode 01: A Womb with a View
Episode 02: Between a Yuk and a Hard Place
Episode 03: The Color of Maddie
Episode 04: Plastic Fantastic Lovers
Episode 05: Shirts and Skins
Episode 06: Take My Wife, for Example
Episode 07: I See England, I See France, I See Maddie's Netherworld
Episode 08: Those Lips, Those Lies
Episode 09: Perfetc
Episode 10: When Girls Collide
Episode 11: In 'N Outlaws
Episode 12: Eine Kleine Nacht Murder
Episode 13: Lunar Eclipse
Moonlighting - Season 5, Episode 03: The Color of Maddie
A woman approaches Blue Moon to find out whether the man she is living with is really her husband. She had married him 10 years ago but he disappeared before suddenly reappearing a few months ago claiming to be her husband.
Genre: Drama, Comedy, Romance, Mystery
Actors: Cybill Shepherd, Bruce Willis, Allyce Beasley, Curtis Armstrong, Kristine Kauffman, Jonathan Ames, Daniel Fitzpatrick, Jamie Taylor, Willie Brown, Jack Blessing, Inez Edwards, ...»
Director: Allan Arkush, Christian I. Nyby II, Paul Krasny, Dennis Dugan, Will Mackenzie, Christopher Hibler, Jay Daniel
#Moonlighting, #Season 5, #Cybill Shepherd, #Bruce Willis, #Allyce Beasley, #Curtis Armstrong
Actors of "Moonlighting - Season 5"
Birthdate: 18 February 1950, Memphis, Tennessee, USA
Birthdate: 19 March 1955, Idar-Oberstein, West Germany
Allyce Beasley
Birthdate: 6 July 1954, Brooklyn, New York, USA
Curtis Armstrong
Birthdate: 27 November 1953, Detroit, Michigan, USA
Kristine Kauffman
Daniel Fitzpatrick
Jamie Taylor
Jack Blessing
Birthdate: 29 July 1951, Baltimore, Maryland, USA
Inez Edwards
Eva Marie Saint
Birthdate: 4 July 1924, Newark, New Jersey, USA
Robert Webber
Birthdate: 14 October 1924, Santa Ana, California, USA
Charles Rocket
Birthdate: 24 August 1949, Bangor, Maine, USA
Clinton Allmon
Birthdate: 13 June 1941, Monahans, Texas, USA
Birthdate: 2 September 1951, Burbank, California, USA
Dennis Dugan
Birthdate: 5 September 1946, Wheaton, Illinois, USA
Birthdate: 11 September 1961, Chicago, Illinois, USA
Birthdate: 8 February 1949, New York City, New York, USA
Bill Marcus
Ronald G. Joseph
Birthdate: 1944, Sacramento, California, USA
Birthdate: 25 November 1947, Jersey City, New Jersey, USA
Tony Bill
Birthdate: 23 August 1940, San Diego, California, USA
Julia Jennings
R.H. Thomson
Birthdate: 24 September 1947, Richmond Hill, Ontario, Canada
Howard Mann
Birthdate: 20 June 1923, New York City, New York, USA
Will Nye
Birthdate: 1 September 1953, USA
Henry G. Sanders
Birthdate: 18 August 1942, Houston, Texas, USA
Frantz Turner
Pamela Bowen
Allan Kolman
Kate Murtagh
Birthdate: 29 October 1920, Los Angeles, California, USA
Michael E. Dawdy
Jensen Collier
Birthdate: 15 May 1953, Knoxville, Tennessee, USA
Leigh Webb
Birthdate: October 19, 1949 in USA
Rob Wickstrom
Rocky Giordani
Zack Phifer
Jack Murdock
Birthdate: 28 October 1922, Ohio, USA
Tammy Brewer
Chris Rennolds
Darwyn Swalve
Birthdate: 20 August 1946, Iowa, USA
Fred Ottaviano
Jack Bannon
Birthdate: 14 June 1940, Los Angeles, California, USA
Birthdate: 11 November 1948, Brooklyn, New York City, New York, USA
Caitlin Clarke
Birthdate: 3 May 1952, Pittsburgh, Pennsylvania, USA
Nicholas Cascone
Birthdate: 20 April 1963, Queens, New York, USA
Ed O'Ross
Birthdate: 4 July 1946, Pittsburgh, Pennsylvania, USA
Gary Cole
Birthdate: 20 September 1956, Park Ridge, Illinois, USA
Nicholas Pryor
Birthdate: 28 January 1935, Baltimore, Maryland, USA
Birthdate: 9 September 1965, Anchorage, Alaska, USA
Leonard Frey
Birthdate: 4 September 1938, Brooklyn, New York, USA
Chino 'Fats' Williams
Birthdate: 26 July 1933, Louisiana, USA
Christine Haber
Barbara Bain
Richard Belzer
Birthdate: 4 August 1944, Bridgeport, Connecticut, USA
Jon Cedar
Birthdate: 22 January 1931, Detroit, Michigan, USA
George Coe
Birthdate: 10 May 1929, Jamaica, Queens, New York City, New York, USA
Pat Corley
Birthdate: 1 June 1930, Dallas, Texas, USA
Birthdate: 13 March 1956, New York City, New York, USA
Robert Ellenstein
Birthdate: 18 June 1923, Newark, New Jersey, USA
Judith Hansen
Gregg Henry
Birthdate: 6 May 1952, Lakewood, Colorado, USA
Alexandra Johnson
Birthdate: 12 April 1947, Brooklyn, New York, USA
Mark Lonow
Birthdate: 11 May 1944, Brooklyn, New York, USA
Cotter Smith
Birthdate: 29 May 1949, Washington, District of Columbia, USA
Lisa Blount
Birthdate: 1 July 1957, Fayetteville, Arkansas, USA
Birthdate: 18 March 1950, Huntington, West Virginia, USA
Ellen Geer
Birthdate: 29 August 1941, New York City, New York, USA
Stephen Godwin
Jim Haynie
Birthdate: 6 February 1940, Falls Church, Virginia, USA
Nora Heflin
Birthdate: 2 February 1950, Los Angeles, California, USA
Marilyn Jones
Birthdate: 6 June 1953, Grosse Pointe, Michigan, USA
Richard Libertini
Birthdate: 21 May 1933, Cambridge, Massachusetts, USA
Will MacMillan
Birthdate: 25 November 1944, Steubenville, Ohio, USA
Kenneth McMillan
Judd Nelson
Birthdate: 28 November 1959, Portland, Maine, USA
J.A. Preston
Birthdate: 13 November 1933, Washington, District of Columbia, USA
Paul Roebling
Birthdate: 1 March 1934, Philadelphia, Pennsylvania, USA
Birthdate: 13 April 1939, Brooklyn, New York City, New York, USA
Granville Van Dusen
Birthdate: 16 March 1944, Grand Rapids, Minnesota, USA
Rona Barrett
Birthdate: 8 October 1936, New York City, New York, USA
Birthdate: 20 July 1957, Alexandria, Virginia, USA
Rhoda Gemignani
Birthdate: 21 October 1940, Philadelphia, Pennsylvania, USA
Ann Hearn
Birthdate: 27 June 1953, Griffin, Georgia, USA
Alan Blumenfeld
Birthdate: 4 September 1952, Rockville Centre, New York, USA
Birthdate: 29 November 1947, Staten Island, New York, USA
Joel Colodner
Birthdate: 1 May 1946, Brooklyn, New York, USA
Sid Conrad
Birthdate: 10 August 1923, Otsego, Michigan, USA
Rick Jason
Birthdate: 21 May 1923, New York City, New York, USA
Robert Joy
Birthdate: 17 August 1951, Montréal, Québec, Canada
Lenore Kasdorf
Birthdate: 27 July 1948, Queens, New York, USA
James MacKrell
Birthdate: 12 October 1937, Little Rock, Arkansas, USA
Joel Polis
Birthdate: 3 October 1951, Philadelphia, Pennsylvania, USA
Birthdate: 16 October 1958, West Covina, California, USA
Phil Rubenstein
Birthdate: 3 August 1940, Bronx, New York, USA
Jonathan Stark
Birthdate: 16 February 1952, Erie, Pennsylvania, USA
More actors


text:
Arafat Had HIV
The personal physician of Yasser Arafat confirmed this weekend that HIV antibodies were present in the former Palestinian leader's blood, adding that it was poison, not AIDS, that killed Arafat in November of 2004 in Paris.
Dr. Ashraf al-Kurdi, who had been Arafat's personal physician for 18 years up until a few weeks prior to his death, claimed in an interview this weekend with Al Jazeera that the leader had been injected with HIV-infected blood prior to his death to cover up the poisoning. Due to French law, Arafat's medical records were never released to anyone outside of his immediate family.
An interview last month with one of Arafat's confidantes revealed that the official cause of death had been a "blood disorder," which may have been HIV.
What Is BG18, and Can It Lead Us to an HIV Vaccine?
Why HIV Rates Dropped 71% Among Gay and Bi Men in the U.K.
California Bill Aims to End the HIV, Hep C and STI Epidemics
Lewd or Clever? Governor Nixes These Utah-Themed Condoms

redpajama_set_name: RedPajamaCommonCrawl


Andreas König is Professor of Strategic Management, Innovation, and Entrepreneurship at the University of Passau, Germany.
Andreas König studies and teaches at the interface of three central topics of strategic management research: (1) strategic leadership in the context of discontinuous technological change, particularly digital transformation; (2) the impact of top executives' characteristics on organizational outcomes (Upper Echelons Theory); and (3) the use of strategic rhetoric, primarily by top executives, and its influence on how constituents evaluate organizations.
His research has appeared in prestigious outlets, including Administrative Science Quarterly, Academy of Management Review, Academy of Management Journal, Research Policy, Journal of Management Studies, Journal of World Business, and MIT Sloan Management Review. He has received numerous national and international awards, including: the The Glueck Best Paper Award by the Strategic Management Division of the Academy of Management in 2011 and 2013 (runner-up in 2012); an Honorable Mention for the Best Conference Paper Prize of the Strategic Management Society and the Best Paper Award of the Cooperative Strategies Division of the Strategic Management Society, 2018; the Fellow Award of the Dr. Theo and Friedl Schöller Research Center for Business and Society in 2012; the Outstanding-Habilitation-Prize by the University of Erlangen-Nuremberg in 2013; the Best Paper Award by the German Academic Association for Business Research (VHB) in 2014; a recognition as runner up for the Best Paper Award at the European Academy of Management (EURAM) in 2017; and the Best Paper Award of the European Academy of Management (EURAM) Special Interest Group Strategic Management in 2017 and the Best Paper Award of the EURAM Track Behavioral Strategy in 2018. Since 2016, he is a member of the Editorial Board of the Academy of Management Review. He collaborates extensively with colleagues from around the world such as Jon Bundy (Arizona State), Theresa Cho (Seoul National University), Albrecht Enders (IMD), Donald C. Hambrick (Pennsylvania State University), Nathan Hiller (Florida International), Nadine Kammerlander (WHU Vallendar), Jonas Puck (WU Vienna), and Tim Quigley (University of Georgia).
Andreas König is a member of the visiting faculties at the Leipzig Graduate School of Management, the Vienna University of Economics and Business, and IMD Lausanne. As researcher, keynote speaker, and executive coach, Andreas König has been working with partners from firms such as BASF, Deutsche Bank, Deutsche Telekom, Douglas Holding, Dr. Oetker, ERGO Direkt Insurances, HOCHTIEF, McKinsey, Nestlé, SAP, Siemens, SCHOTT, Schüco, Telefónica, ThyssenKrupp, and Volkswagen. He also cooperates closely with a number of start-ups and non-profit organizations.
Both his scholarly and his educational work are significantly influenced by his uniquely diverse experiences, particularly as a professional musician, which he made prior to entering the field of business studies. After studying classical trumpet at the Rotterdam Conservatoire, Andreas König completed a degree as Master of Music at the Royal Academy of Music and King's College, London. As a musician, he was especially influenced by his professors Edward Carroll, John Wallace, Howard Snell, and Ray Allen, and he participated in numerous masterclasses, for instance with Peter Herbolzheimer, Ack and Jerry van Rooyen, Thomas Stevens, James Thompson, and The Canadian Brass. He played solo recitals in places such as St Paul's Cathedral, London, the Cathedral of Palma de Mallorca, and St Nicolas' Church in Leipzig. He recorded several CDs and performed under the batons of conductors such as Sir Colin Davies, Lord Yehudi Menuhin, and Valery Gergiev. To complement his music studies, Andreas König visited lectures in protestant theology, classical philosophy and philology at the Universities of Bonn, Madrid, and Leiden.
Andreas König is married and has four children.
Apply until April 7th for our workshop "Managerial Communication"


text:
Q: Return MAX date of two cells, IF BLANK return "need to complete" Having trouble figuring out a formula to accomplish this. Tried a lot of different things.
Return MAX date of (R3,T3) IF BLANK return "need to complete". Any and all help is appreciated, thank you.

A: Use OR to test if blank
=IF(OR(R3="",T3=""),"Need to complete",MAX(R3,T3))

redpajama_set_name: RedPajamaStackExchange


text:
George E. Scott (July 3, 1860 – November 9, 1915) was a member of the Wisconsin State Assembly and the Wisconsin State Senate.

Biography
Scott was born on July 3, 1860, in Durand, Wisconsin. He died at his home in Prairie Farm, Wisconsin, on November 9, 1915.

Career
Scott was elected to the Assembly in 1904 and was re-elected in 1906 and 1908. Later, he was elected to the Senate in 1910 and re-elected in 1914. He was a Republican.

References

People from Durand, Wisconsin
People from Barron County, Wisconsin
Republican Party Wisconsin state senators
Republican Party members of the Wisconsin State Assembly
1860 births
1915 deaths
19th-century American politicians

redpajama_set_name: RedPajamaWikipedia


UPDATE: The battle over Left Shark is not over yet! Upon closer examination, last week's trademark-related denial involved only one of six classes (Class 41 for "live musical and dance performances") covered in Katy Perry's application to register a front view of the Left Shark. The Patent and Trademark Office rejected the specimen she submitted to prove use of the image as a service mark. The specimen in question was a photograph taken from the Super Bowl performance. Despite this initial rejection all of Perry's applications are still very much in play.


text:
Suicide Squad 2 Cast Adds Idris Elba as New Deadshot
By Jeff Scott On Mar 7, 2019 10:39 AM EST
News broke late last week that Will Smith would no longer be serving as the character Deadshot within the DCEU. But it apparently hasn't taken long for the sequel's director, James Gunn, to find a replacement. Reports are that Idris Elba is now joining the Suicide Squad 2 cast as Deadshot, replacing Smith.
The Hollywood Reporter broke the news yesterday evening that Gunn recently met with Elba to discuss the role. Things reportedly went so well during their meet last week that talks have already escalated to the studio level, with discussions now ongoing between Warner Bros. and Elba's representation.
Will Smith was essentially the lead of David Ayer's 2016 Suicide Squad. However, it was Margot Robbie's Harley Quinn that stole the show. The movie did incredibly well in the box office, raking in roughly $746.8 million on a budget of $175 million for Warner Bros.
Critically though, it didn't fare nearly as well. Rotten Tomatoes lists an approval rating of 27% with Metacritic placing it at a review average of 40. Which is likely one of the reasons why Warner Bros. hasn't been overly aggressive in getting a sequel out to theaters. But now that James Gunn is on board to write and direct, things have changed.
The Hollywood Reporter states that Warner Bros. is "extremely high" on the script that Gunn submitted. Thus explaining their enthusiasm in getting production going as soon as possible. Adding a name like Idris Elba to the Suicide Squad 2 cast only furthers that narrative.
The Suicide Squad 2 cast will see the return of Robbie in the now iconic role of Harley Quinn. But other than she and Elba, the remainder of the roster is up in the air. There have been mixed reports as to whether the team's leader, Rick Flagg, would be back. And if the character did return, it's unclear if Joel Kinnaman would be reprising the role.
Things should begin falling into place quickly as Warner Bros. makes the project more of a priority. James Gunns' Suicide Squad 2 is currently listed with a release date of August 6, 2021.
Source The Hollywood Reporter
DCMovie NewsSuicide SquadWarner Bros
Growing up a 90's kid, Jeff found his love for gaming during Nintendo's heyday. Because of that, you could (perhaps sadly) call him a "Nintendo Fanboy" to this day.
50 Best Bob's Burgers Gifts: The Ultimate List (2020)
New Rage 2 Trailer Shows Off All Your Awesome Arsenal
How to Stream Home Alone in 2019 (Updated!)
Rambo: Last Blood Trailer Promises Death is Coming
Annabelle Comes Home Trailer Is Here to Possess Us All
Sonic Movie Delay Pushes it to February
Knights of the Old Republic Movie Sets Writer
The New Mutants: Comic Book Origins, Members, Abilities, And More


text:
Dead dogs found inside Florida home abandoned since Hurricane Irma
"I can't believe that somebody would leave three to six dogs in there to just starve to death like that," Kirby said.
Signs placed on the garage of a Weeki Wachee home where deputies found several dead dogs this week. {Photo courtesy of Lisa Kirby]
The Hernando County Sheriff's Office is investigating how several dogs were left to die inside a seemingly abandoned house in Weeki Wachee. It appears that a construction crew working nearby spotted one of the deceased dogs through a window. Authorities are still investigating and have not said how many dogs were inside or revealed a cause of death. [Megan Reeves | Times]
By Jonathan Capriel and TyLisa C. Johnson
Published March 9 2018
Updated March 10 2018
WEEKI WACHEE — Neighbors said they hadn't seen the woman in the house on Robina Road since Hurricane Irma blew through the area in September.
Then, on Tuesday, a construction worker peered in a window and made a grisly discovery: the carcass of a dog. Inside were at least two more.
The Hernando County Sheriff's Office is investigating how dogs were left to die inside a seemingly abandoned house in Weeki Wachee. Authorities have not yet revealed a cause of death, or even said who owned the pets.
"It is unknown how many dogs there were as they were in the advanced stages of decomposition," said Denise Moloney, a Sheriff's Office spokeswoman.
Hernando County records show the home, at 11980 Robina Road, is owned by Lauren Wendy Kopp, 35, who has claimed it as her primary residence for a homestead exemption since 2012.
Kopp could not be reached for comment. An attorney representing her, James P. Mancuso, said she is "distraught" and asking for privacy.
He said Kopp allowed someone "down on his luck" to move into the home. An investigator at the firm said Kopp moved in with a boyfriend in September.
"Ms. Kopp is horrified and deeply saddened about this tragedy," Mancuso wrote, "and she hopes that the person or people responsible for this crime are brought to justice. Ms. Kopp was not involved in any way with the death of the dogs, and she is not a suspect in this matter. She has cooperated and will continue to cooperate fully with the authorities in any way she can to assist in their investigation."
He said Kopp has a long history of being an animal lover and would never do anything to cause harm to an animal.
Next-door neighbor Patt Pierce said there has not been a light on in the house since September.
The Sheriff's Office visited Kopp's house months earlier, on May 27, after Pierce called expressing concern. The dispatcher noted a caller "STATING DOG IN THIS GARAGE AND NOT SURE IF ANYONE HAS EVER LET IT OUT."
"I could hear them barking," Pierce said Friday. "It gets hot in May. I wanted someone to do a welfare check on the dogs."
An entry the next morning reflected that the agency talked to Kopp, who said her dogs were not abandoned. She said she works late and lets the dogs out at night.
Pierce said she saw her neighbor move out in September but assumed she took the dogs with her.
"If I would have known there were dogs in there I would have busted down the door," she said.
Kopp's ex-boyfriend, Michael Oliveira, 46, said a detective visited him Friday and showed him photographs of dog remains found at the house.
Both Oliveira and the law firm investigator, Frank Hirst, told the Tampa Bay Times that two dogs were in the home's laundry room and another was in the living room. But the investigator disputed something else Oliveira said — that he recognized those dogs, pit bulls or pit mixes, as pets he once shared with Kopp.
"Just because I say the sky is purple doesn't mean it's true," Hirst said of the claim.
Oliveira said he and Kopp broke up in 2014 after nine years. Sheriff's records show a sometimes tumultuous relationship.
The couple lived at the home for several years, Oliveira said. He left dogs with Kopp after the breakup, he said.
"I would never think in a million years she would be capable of forgetting these animals," Oliveira said.
The investigator said Kopp had surrendered her dogs to a rescue group before moving, and that she is busy trying to track them down to clear her name.
Another of Kopp's neighbors, Christopher Kirby, said that, like Pierce, he and his wife didn't see anyone living in the house after Kopp left.
Kirby said Hernando County Animal Services and the Sheriff's Office visited the house Tuesday and then returned Wednesday to remove the carcasses.
Contact Jonathan Capriel at (813) 225-3141 or jcapriel@tampabay.com. Follow @jonathancapriel.
In South Florida: Dogs left chained to trees as owners fled hurricane
In Tampa Bay: As Irma howled, some dogs and cats got lost
A Tough Choice: A man and his dog, to shelter or not?
A Happy Ending: This dog's owner dyed its hair purple, and nearly killed it
Jonathan Capriel
Times Staff Writer
TyLisa C. Johnson
Oops? Apollo 11 hit its mark, but did editors miss with headline for moon landing?
'Moon, We're Onto You' headline inappropriate for historic event, some Times staffers felt
How to celebrate the Apollo 11 moon landing in Tampa Bay and on TV
The 50th anniversary of the moon landing will be the center of parties at MOSI, other local events and TV shows.
Does Pinellas school leader Mike Grego want to be Hillsborough's superintendent? He's not saying no.
He said he hasn't thought about applying for the top schools job in neighboring Hillsborough County. But he will "at the appropriate time."


Welcome to the Amrita Vishwa Vidyapeetham Virtual Lab online feedback system. Thanks for taking the time to share your feedback. We'll use the information you provide below to improve our virtual labs.
How do you rate the online performance of the experiment?
To what extent did you have control over the interactions?
To what degree was the actual lab environment simulated?
Was the measurement and analysis of data easy for you?
Were the links provided consistent with the objectives of the experiment?
Were the results of the experiment easily interpreted?
How helpful do you feel the system is?
Did you feel confident enough while performing the experiment?
Was the experiment/process motivating enough?
Did you go through the manual/ step by step procedure before performing the experiments live?
Did you get the feel of a real lab while performing the experiments virtually?
Did you feel the absence of an instructor?
Could you run the experiments smoothly, i.e., without interruptions?
Could you measure and analyse the data successfully?
Did you follow the step by step procedure before doing the live experiment?
Could you compare your results with the given typical results?
Do you think performing experiments through virtual labs were more challenging than the real lab experiments?
Specify three problems/difficulties you faced while performing the experiments?
Describe three interesting things about the experiments.
Do you think doing experiments through virtual lab gives scope for more innovative and creative research work?


text:
package org.apache.tiles.request.portlet.delegate;

import java.util.Collection;
import java.util.Map;
import java.util.Set;

/**
 * Parameter map to be used when the response is a {@link javax.portlet.StateAwareResponse}.
 *
 * @version $Rev$ $Date$
 */
public class StateAwareParameterMap implements Map<String, String[]> {

    /**
     * The request parameter map.
     */
    private Map<String, String[]> requestMap;

    /**
     * The response parameter map.
     */
    private Map<String, String[]> responseMap;

    /**
     * Constructor.
     *
     * @param requestMap The request parameter map.
     * @param responseMap The response parameter map.
     */
    public StateAwareParameterMap(Map<String, String[]> requestMap,
            Map<String, String[]> responseMap) {
        this.requestMap = requestMap;
        this.responseMap = responseMap;
    }

    @Override
    public void clear() {
        responseMap.clear();
    }

    @Override
    public boolean containsKey(Object key) {
        return requestMap.containsKey(key);
    }

    @Override
    public boolean containsValue(Object value) {
        return requestMap.containsValue(value);
    }

    @Override
    public Set<java.util.Map.Entry<String, String[]>> entrySet() {
        return requestMap.entrySet();
    }

    @Override
    public String[] get(Object key) {
        return requestMap.get(key);
    }

    @Override
    public boolean isEmpty() {
        return requestMap.isEmpty();
    }

    @Override
    public Set<String> keySet() {
        return requestMap.keySet();
    }

    @Override
    public String[] put(String key, String[] value) {
        return responseMap.put(key, value);
    }

    @Override
    public void putAll(Map<? extends String, ? extends String[]> m) {
        responseMap.putAll(m);
    }

    @Override
    public String[] remove(Object key) {
        return responseMap.remove(key);
    }

    @Override
    public int size() {
        return requestMap.size();
    }

    @Override
    public Collection<String[]> values() {
        return requestMap.values();
    }
}

redpajama_set_name: RedPajamaGithub


text:
Plagiomnium, selten Kriechsternmoose, ist eine Gattung von Laubmoosen aus der Familie Mniaceae mit weltweiter Verbreitung.

Beschreibung
Die Pflanzen dieser Gattung sind grün, nie rötlich. Fertile Triebe sind aufrecht und an der Spitze meist schopfig beblättert, sterile Triebe wachsen oft bogig überhängend oder niederliegend und sind häufig scheinbar zweizeilig beblättert. Die Blattränder sind 2- bis 5-zellreihig gesäumt. Sporenkapseln sind eiförmig bis länglich und waagrecht bis hängend.

Systematik
Zur Gattung Plagiomnium werden weltweit 25 Arten gezählt.

In Europa sind 9 Arten vertreten, darunter:
 Plagiomnium affine
 Plagiomnium cuspidatum
 Plagiomnium elatum
 Plagiomnium ellipticum
 Plagiomnium medium
 Plagiomnium rostratum
 Plagiomnium undulatum

Die habituell ähnlichen und miteinander nahe verwandten Arten Plagiomnium affine, Plagiomnium elatum, Plagiomnium ellipticum und Plagiomnium medium werden auch zur Artengruppe Plagiomnium affine agg. zusammengefasst.

Quellen

Literatur
 Jan-Peter Frahm, Wolfgang Frey: Moosflora (= UTB. 1250). 4., neubearbeitete und erweiterte Auflage. Ulmer, Stuttgart 2004, ISBN 3-8252-1250-5.
 Martin Nebel, Georg Philippi (Hrsg.): Die Moose Baden-Württembergs. Band 2: Spezieller Teil, (Bryophytina II, Schistostegales bis Hypnobryales). Ulmer, Stuttgart 2001, ISBN 3-8001-3530-2.

Einzelnachweise

Weblinks

Mniaceae (Familie)
Mniaceae


text:
MegaFon opens subscription for ruble bonds
Public Joint Stock Company "MegaFon" (MoEx: MFON), a pan-Russian operator of digital opportunities ("MegaFon" or the "Company"), announces the opening of the subscription book for its exchange bonds ("Ruble bonds").
This announcement is for information purposes only and does not constitute an offer to sell or an invitation to purchase securities in, or to persons from, the United States, the United Kingdom, the Russian Federation or elsewhere. Any such offer or invitation is made only by the documentation for the exchange bonds which has been duly registered by the Moscow Exchange and publicly disclosed in accordance with applicable laws and regulations.
Laws in certain jurisdictions may impose restrictions on the distribution of this announcement and persons who come into possession of this announcement or obtain other information given herein should familiarize themselves with any such restrictions and fully comply with them. Any failure to comply with these restrictions may constitute a violation of the laws of any such jurisdiction.
Ruble bonds amounting to 20 billion rubles are being offered. The Ruble bonds will have a term of 3 years following placement. The coupon is expected to be in the range between 08.60% and 08.70% per annum, subject to final determination via the book building exercise. Proceeds from the Ruble bonds will be used for general corporate purposes.
The books are expected to close at 16:00 Moscow time today. Placement on the Moscow Exchange is expected to occur on or about04 February 2019.
Credit Bank of Moscow, Gazprombank, Otkritie Bank, Raiffeisenbank and Sberbank CIB are acting as the lead arrangers of the Ruble bonds issue. Gazprombank is acting as the placement agent.
The Ruble Bonds are offered under an exchange bonds programme admitted to trading on the Moscow Exchange on 20 April 2016, as earlier announced on the Company's website: http://corp.megafon.com/investors/news/capital_market_releases/20160422-1553.html.
Director of Investor Relations and M&A
Head for Corporate Communications
MegaFon PJSC is a leading Russian integrated telecommunication service provider, operating in all segments of the telecommunications markets in Russia, and in the Republics of Abkhazia, South Ossetia and Tajikistan. MegaFon is a recognized market leader in the provision of mobile data services, was the first operator in Russia to launch commercial operation of a third generation (3G) network and was the first operator in the world to launch commercial operation of an LTE-Advanced (4G) data network. MegaFon is traded on the Moscow Exchange under the symbol MFON. Additional information about MegaFon and the products and services provided by MegaFon can be found at https://www.megafon.ru
Cautionary Statement Regarding Forward Looking Statements
Some of the information in this document may contain or refer to projections or other forward-looking statements regarding future events or the future financial performance of the Company. You can identify forward looking statements by terms such as "expect", "believe", "anticipate", "estimate", "forecast", "intend", "will", "could", "may", or "might" the negative of such terms or other similar expressions. The Company wishes to caution you that these statements are only predictions, and are based upon various assumptions which are inherently subject to significant uncertainties and contingencies, which are difficult or impossible to predict, and are beyond our control. We may not achieve or accomplish these plans or predictions. The Company does not necessarily intend to update these statements to reflect events and circumstances occurring after the date hereof or to reflect the occurrence of unanticipated events. Many factors could cause the actual results to differ materially from those contained in projections or forward-looking statements of the Company, including, among others, general economic conditions, the competitive environment, risks associated with operating in Russia, rapid technological and market change in the industries in which the Company operates, as well as many other risks specifically related to the Company and its business and operations.
Statement Regarding Inside Information
Some of the information in this document may be inside information. The subject matter, the identity of the issuer, the identity of the persons making the notification and their titles, and the date and time of the notification are all as set forth above.


The new Prancing Horse single seater was officially unveiled by the Scuderia Ferrari Marlboro in front of the Italian and world press at Mugello. The new car will compete in the next Formula 1 world championship. The new 248 mark indicates the engine characteristics: 2.4 liter, 8 cylinder.
Then came Aldo Costa, creator of the 248 F1, to reflect on Byrne's role and the characteristics of the car in detail. He declared that: 'it was mainly to do with the V8 engine and we imposed a radical change from both a mechanical and aerodynamic point of view. The aerodynamics are still at a preliminary stage and will be until the first race of the season. As regards the chassis, this is totally new, above all in the centre section. We decided on this in order to optimize the weight distribution and lighten the entire structure. The same goes for the suspension, especially in the completely redesigned rear end. The transmission too is all new (though constructed from composite materials) and also the differential. In building these two new elements in particular, we had to pay close attention to the characteristics of the V8. The greater vibrations generated by the engine brought more initial problems'.
The gathered journalists then asked questions to which Brawn replied that 'from the midway point of last season when we realized we could not challenge for the top spots, we began concentrating more on development, especially the blend of the aerodynamic configuration and the characteristics of the new V8. Despite the progress that the Bridgestone tires have made with the reintroduction of tire changes, we expect to see lap times that are a second or two slower than last year'.
After Aldo Costa, Ross Brawn and Rory Byrne came Paolo Martinelli, Formula 1 Engine Director, and Gilles Simon, head of planning and engine development, to face the journalists during the press conference to launch the new 248 F1.
'It is a totally new project', began Martinelli. 'It is a return to the past, as the name of the car demonstrates. We started working on this engine midway through 2004 and then tested it on the bench. Last August it made its first outing, at Fiorano, and in the autumn of 2005 we completed the V8. Now we are close to the final version. Obviously, in the course of the season we will have to cope with a very steep learning curve. Gilles Simon's success in development was underlined: 'the calculations were made long ago and even if the regulation changes were related to us rather late in the day, fundamental modifications such as the selection of the centre of gravity had already been made'. 'The rules outline global constraints but do allow a lot of space for projectual experimentation', continued Martinelli.
'The 90° angle was our choice as was settling on the minimum weight for the non-moving parts. The real challenge, however, was lightening the weight of the moving components'. 'For the first time in ten years a drop in performance was recorded and this was fundamental. The change in power meant some greater investment, but, in the long run, it will be more economical. The overall output of the engine remains unchanged and so some factors were the same as on the V10′. Martinelli also revealed that there had been some dialogue between the engineers who work on road-going cars and those who concentrate on racing models. 'We met the people who work on GTs and exchange opinion in analyzing problems and the methods to resolve them. It was by no means a one-way communication' 'We were certainly on shared ground', added Simon. 'However, there are many differences, for example in our time schedules. We made a lot of input and so did they. It was a process of cross contamination'.


text:
<script src="../three.js/build/three.js"></script>
<script src="../three.js/examples/js/Detector.js"></script>
<script src="../three.js/examples/js/curves/NURBSCurve.js"></script>
<script src="../three.js/examples/js/curves/NURBSSurface.js"></script>
<script src="../three.js/examples/js/curves/NURBSUtils.js"></script>
<script src="../three.js/examples/js/loaders/ColladaLoader.js"></script>
<script src="../three.js/examples/js/libs/pnltri.min.js"></script>

<script>

/**
 * HTML imports three.js library
 * @homepage https://github.com/arodic/three-js
 * @demo http://akirodic.com/components/three-js/demo.html
 */

THREE.ShapeUtils.triangulateShape = (function() {
	var pnlTriangulator = new PNLTRI.Triangulator();
	return function(contour, holes) {
		// console.log("new Triangulation: PnlTri.js " + PNLTRI.REVISION );
		return pnlTriangulator.triangulate_polygon([contour].concat(holes));
	};
})();

</script>


F1 chief Max Mosley has announced that from 2008 onwards, now hold your breath, Microsoft (yeah, you read it right, Microsoft) will be the official supplier of engine control units.
Now that takes the word "crashing" to a whole new level. Doesn't it!!
Also, going by Microsoft's record the 2008 season may well begin in 2009 if all goes well following the Vista way!!


Inspired by listening at great length to a box set of NASA recordings while making some of my Voice On Record radio shows for Resonance FM, and later from hearing Ben Burtt's edited version of the sound recordings from the booster stages of a Space Shuttle launch, I wrote instructions a structured improvisation piece.
I promoted and did the sound projection for the Scottish premiere of Karlheinz Stockhausen's "Hymnen" for four-channel tape. The concert included a short talk about the piece after which I played Regions I and II followed by an interval, and the Regions III and IV.
I used a Maihak W66c fader to control the overall volume level via the Metric Halo sound card. This is the same type of fader used in the WDR STudio for Electronic Music from the 1950s through to the late 1970s, so provided a nice connection to the performance practice used in the studio realisation of the piece.
8 channel sound installation commissioned by Botanic Productions as part of Dee Isaacs' "Watching" - an opera for children.
Sounds recorded around the world at around 3 o'clock in the morning were combined in an 8-channel setup in the Orchid House. Audience members walked through the space between set-piece scenes and the overall time taken was around 4 minutes. The installation was designed to last 12 minutes so this was edited down, eventually increasing the density of sounds.


text:
Q: clear login details of user for each login I am building an app and I want to clear user login details of Facebook for user.Because once it saves details it uses same details each time but I want is that it should ask user to login every time user opens the app ?

A: Write following statements along with Webview defined.
myWebView.clearCache(true);
myContext.deleteDatabase("webview.db");
myContext.deleteDatabase("webviewCache.db");

A: If you are not using any jar and using library classes then following is the code snippet for your understanding.
From Facebook.java
Static variables that are used to call the activity for log in dialog.
 public static final int FORCE_DIALOG_AUTH = -1;

 private static final String LOGIN = "oauth";

 // Used as default activityCode by authorize(). See authorize() below.
 private static final int DEFAULT_AUTH_ACTIVITY_CODE = 32665;

following is the authorize method of this class to authorize a user and instead of using DEFAULT_AUTH_ACTIVITY_CODE if you use FORCE_DIALOG_AUTH your app will prompt you for log-in every time.
 /**
 * Authorize method that grants custom permissions.
 *
 * See authorize() below for @params.
 */
public void authorize(Activity activity, String[] permissions,
        final DialogListener listener) {
    authorize(activity, permissions, DEFAULT_AUTH_ACTIVITY_CODE, listener);
}

another authorize method in this Facebook.java class is as follow and this method cause you for single sign on (SSO). For more information you can check this method's comments that I have included in this answer.
/**
 * Full authorize method.
 *
 * Starts either an Activity or a dialog which prompts the user to log in to
 * Facebook and grant the requested permissions to the given application.
 *
 * This method will, when possible, use Facebook's single sign-on for
 * Android to obtain an access token. This involves proxying a call through
 * the Facebook for Android stand-alone application, which will handle the
 * authentication flow, and return an OAuth access token for making API
 * calls.
 *
 * Because this process will not be available for all users, if single
 * sign-on is not possible, this method will automatically fall back to the
 * OAuth 2.0 User-Agent flow. In this flow, the user credentials are handled
 * by Facebook in an embedded WebView, not by the client application. As
 * such, the dialog makes a network request and renders HTML content rather
 * than a native UI. The access token is retrieved from a redirect to a
 * special URL that the WebView handles.
 *
 * Note that User credentials could be handled natively using the OAuth 2.0
 * Username and Password Flow, but this is not supported by this SDK.
 *
 * See http://developers.facebook.com/docs/authentication/ and
 * http://wiki.oauth.net/OAuth-2 for more details.
 *
 * Note that this method is asynchronous and the callback will be invoked in
 * the original calling thread (not in a background thread).
 *
 * Also note that requests may be made to the API without calling authorize
 * first, in which case only public information is returned.
 *
 * IMPORTANT: Note that single sign-on authentication will not function
 * correctly if you do not include a call to the authorizeCallback() method
 * in your onActivityResult() function! Please see below for more
 * information. single sign-on may be disabled by passing FORCE_DIALOG_AUTH
 * as the activityCode parameter in your call to authorize().
 *
 * @param activity
 *            The Android activity in which we want to display the
 *            authorization dialog.
 * @param applicationId
 *            The Facebook application identifier e.g. "350685531728"
 * @param permissions
 *            A list of permissions required for this application: e.g.
 *            "read_stream", "publish_stream", "offline_access", etc. see
 *            http://developers.facebook.com/docs/authentication/permissions
 *            This parameter should not be null -- if you do not require any
 *            permissions, then pass in an empty String array.
 * @param activityCode
 *            Single sign-on requires an activity result to be called back
 *            to the client application -- if you are waiting on other
 *            activities to return data, pass a custom activity code here to
 *            avoid collisions. If you would like to force the use of legacy
 *            dialog-based authorization, pass FORCE_DIALOG_AUTH for this
 *            parameter. Otherwise just omit this parameter and Facebook
 *            will use a suitable default. See
 *            http://developer.android.com/reference/android/
 *              app/Activity.html for more information.
 * @param listener
 *            Callback interface for notifying the calling application when
 *            the authentication dialog has completed, failed, or been
 *            canceled.
 */
public void authorize(Activity activity, String[] permissions,
        int activityCode, final DialogListener listener) {

    boolean singleSignOnStarted = false;

    mAuthDialogListener = listener;

    // Prefer single sign-on, where available.
    if (activityCode >= 0) {
        singleSignOnStarted = startSingleSignOn(activity, mAppId,
                permissions, activityCode);
    }
    // Otherwise fall back to traditional dialog.
    if (!singleSignOnStarted) {
        startDialogAuth(activity, permissions);
    }
}

EDIT:

I am talking about the inline facebook library as shown above pic. you have to change from DEFAULT_AUTH_ACTIVITY_CODE to FORCE_DIALOG_AUTH to make your app to ask credential every time you request facebook.

A: Hello Amit,

When you login in facebook then facebook gave you "SessionId" and
  facebook use this session every time.
if you want every time login then you can write a "Logout" code at the
  back button of Activity.


English is definitely the language of universal interaction , and billions of people use the language continuously for many reasons . One of the most serious threats that a number of students , instructors, authors, hired professionals and business people experience is a demand to have a good level of written English . It is possible to notice an obvious paradox: for one part, only a few people who practice the language for a job or learning have the Internet – grammarservices.com will definitely make your stylistics excellent and writing grammatically correct .
One of the recent novelties in the digital sphere is a checking tool for plagiarism. To perceive the sense of the tool, it is necessary to check my essay provide answers to two major issues : what the main purpose of using plagiarism checker is and why it is recommended to check papers for plagiarism. Any text which can be accessed by scholars and professionals is the private intellectual property of the author . Copying even the most insignificant part of the text in case citations are absent or wrong is equal to IP theft. Online plagiarism checker is a technology which performs the deep analysis of the uploaded documents in order to find similarities with the texts that exist in the Web .
If for whatever reason the receiveris mailing address is unavailable, email maybe your selection.
Learners – obtain a habit of checking documents for plagiarism daily every time you create researches or course works . "If I do not check my work on the subject of originality, my professor will certainly perform it for me " – it is the learner`s motto of the latest years .
All teachers are likely to decrease marks in case even the slightest portion of appropriation has been discovered . It is worth adding that copying can frequently be accidental that is why the best thing will be enter the document content to the free of charge \ costless plagiarism checker for students – grammarservices.com in order to make sure the turned document \ the file content is entirely unique.
Writers – examine articles , releases or a variety f many different texts for a unique character , it is worth using a free online plagiarism checker . Plagiarized files turned by copywriters can result in severe penalties in addition to losing a good reputation.
Businessmen – they prefer to use a plagiarism detector in case they need to create any piece of original text for the advertised products .
What is the most trusted plagiarism tool? One can select among plenty of similar tools available that have a seeming similarity . Nevertheless , different tools can be distinguished in terms of deployment, ease of use and effectiveness . The key points that you can bear in mind are that the tool is to be available on the Internet and that it must be costless.
She worked relentlessly to make audio that has been unique..
Regarding the productivity, one is unable to make sure of this aspect before you try .
This hint that is additional would be to simply deliver the email to those that want it.
grammarservices.com is currently considered one of the most reliable web-based solutions the purpose of which is checking for plagiarism . Take a try of the free online checker and test the effectiveness by yourself !
How can I check the document originality ? with the help of grammarservices.com it is the work of seconds : one only has to enter your text in the special field or transfer the file that is under checking. The trusted service is to do the whole checking procedure for you and will provide you with the outcome as soon as possible .
Discovering grammar-based, spelling, punctuation and spanish spell check style-based mistakes.
Amending all types of errors depending on user`s directions , in case of a necessity .
grammarservices.com is of a great help to everybody who feels a desire to improve his writing and to become convinced in the text`s entire uniqueness.


text:
The Lonely Film Critic
Sounds of solitary cinema
Weekly Spotlight #4: Smithereens (Seidelman, 1982)
by Tomas Trussow
In this weekly series, The Lonely Film Critic highlights an older release of interest, whether it be an oft-overlooked gem or a classic worth revisiting. This week we recommend Susan Seidelman's bracing Felliniesque debut, which is set during the waning years of the New York punk scene.
Smithereens travels the hardest roads. It doesn't allow its protagonist to achieve her goals and makes her scrabble and clamour for a place in the world. But it also asks if those goals are at all noble, and if her place in life is the one she sees for herself. She does not, after all, know exactly what she wants, other than a notional ideal of fame and notoriety (which she believes she can get easily by becoming a band's groupie). Whatever talents she may possess we do not ever come to know. We do get to know all her bad traits: the way she exploits the people around her without trying to earn a decent living, the way she seeks to find the easiest solutions for her problems, the way she has no scruples in turning to crime to get what she wants. She is adrift in more ways than one, and the sad part about it all is that she's burned so many bridges that no one is willing to help her turn over a new leaf. Nor does she seem to care about doing so. Before anyone has a chance to offer alternatives, she repeatedly leaves in a huff, lying that she has a million-and-one other places to go. Her stubbornness and pride are but two more vices to add to her catalogue, and two more reasons why her journey in this film is so unsuccessful.
Despite being a downer of a story, Smithereens casts a beguiling spell as an everlasting record of the shifting punk scene in America during those days. Seidelman recreates the era's grubby mystique with unflinching fidelity and brings it to life for people (such as myself) who may not have lived through it themselves. The sounds, the styles and the attitudes are on full display, defiant and rambunctious in much the same way Wren is. Further to that is Susan Berman's irresistible performance as our untrustworthy lead. Rocking red hair and even redder kicks, she becomes a small whirlwind of chaos that we cannot turn away from, try as we may. I was shocked to learn her acting career was so short-lived. This is the kind of performance that nowadays would rocket someone to the very top. But perhaps it was meant to be this way, because this will forever be her role. Sometimes it's not so bad being a one-hit wonder, because at least your name is always going to be attached to a work of great quality.
Sure, in the end this film leans heavily on Fellini's Nights of Cabiria as a source of inspiration, but there's enough here to make it its own animal. Plus, while the Fellini ends on a broken smile, this one is assuredly much grimmer. There's no telling if Wren will ever smile again after the events that transpire.
Smithereens is currently available on Blu-ray and DVD from Criterion and can also be streamed on The Criterion Channel.
05.06.2019 – Reviews / Weekly Spotlight / 1980s / 1982 / Brad Rijn / Drama / Richard Hell / Susan Berman / Susan Seidelman
Categories Select Category Awards (4) Festivals (24) Reviews (335) Weekly Spotlight (13)
Enter your email address to subscribe to The Lonely Film Critic and receive notifications of new posts by email.
Phantom Thread (Anderson, 2017)
Weekly Spotlight #11: The Prime of Miss Jean Brodie (Neame, 1969)
TIFF Review: The Personal History of David Copperfield (Iannucci, 2019)
The Greatest Showman (Gracey, 2017)
Julieta (Almodóvar, 2016)
Predicting the 92nd Academy Awards: The Nominations
Downton Abbey (Engler, 2019)
Judy (Goold, 2019)
Brittany Runs a Marathon (Colaizzo, 2019)
Follow The Lonely Film Critic on WordPress.com
Copyright ©2017-2019 The Lonely Film Critic. All rights reserved.


text:
Cytomegalovirus Retinitis Market
Cytomegalovirus Retinitis Market - Forecast(2023 - 2028)
Cytomegalovirus (CMV) Retinitis is caused by a herpes-type virus, cytomegalovirus infection that affects the retina of the human eye among patients having a weak immune system. Globally, growing awareness among people for different types of eye diseases, rise in the incidences of HIV infection and cytomegalovirus retinitis cases, and increasing government initiative for healthcare infrastructure and enhancement of healthcare facilities are the prime growth drivers of global biosensors market. In addition, increase in cases of Cytomegalovirus Retinitis, and emerging economies such as China, India and others, will create new opportunities for global biosensors market. However, higher cost of the research and development, risk of drug resistance, increase in anti-HIV medications, which prevent occurrence of this disease, and lack of healthcare insurance are the key restraints for global biosensors market.
This report identifies the global biosensors market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to global biosensors market.
Geographically North America dominated global biosensors market, and Asia Pacific is projected to have fastest growth, owing to rapidly increasing aging population, awareness among people for various types of eye diseases, and high prevalence rates for immunodeficiency diseases in this region. Among all the treatment, anti-CMV Oral Ganciclovir has the highest market share in global biosensors market.
This report segments global biosensors market on the basis of drugs, treatment, route of administration, dosage form, and regional market as follows:
Cytomegalovirus Retinitis Market, By Drug: Foscarnet, Ganciclovir, Cidofovir, Fomivirsen, and Others
Cytomegalovirus Retinitis Market, By Treatment: Anti-CMV Oral Ganciclovir, Anti-CMV Intravenous Drug Therapy, Anti-CMV Intraocular (local), Anti-HIV Systemic, and Retinal Detachment Through Vitrectomy
Cytomegalovirus Retinitis Market, By Route of Administration: Systemic, and Ocular
The report has focused study on biosensors market by basis of dosage form such as: Capsule, Implant, Solution, Tablet, and Others
This is report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region
Sample Companies Profiled in this Report are:
Bausch & Lomb Incorporated
Valeant Pharmaceuticals International, Inc.
Luitpold Pharmaceuticals, Inc.
F. Hoffman La-Roche Ltd.
Endo Pharmaceuticals, Inc.
1. Cytomegalovirus Retinitis Market - Overview
1.1. Definitions and Scope
2. Cytomegalovirus Retinitis Market - Executive summary
2.1. Market Revenue, Market Size and Key Trends by Company
2.2. Key Trends by type of Application
2.3. Key Trends segmented by Geography
3. Cytomegalovirus Retinitis Market
3.1. Comparative analysis
3.1.1. Product Benchmarking - Top 10 companies
3.1.2. Top 5 Financials Analysis
3.1.3. Market Value split by Top 10 companies
3.1.4. Patent Analysis - Top 10 companies
3.1.5. Pricing Analysis
4. Cytomegalovirus Retinitis Market – Startup companies Scenario Premium
4.1. Top 10 startup company Analysis by
4.1.1. Investment
4.1.2. Revenue
4.1.3. Market Shares
4.1.4. Market Size and Application Analysis
4.1.5. Venture Capital and Funding Scenario
5. Cytomegalovirus Retinitis Market – Industry Market Entry Scenario Premium
5.1. Regulatory Framework Overview
5.2. New Business and Ease of Doing business index
5.3. Case studies of successful ventures
5.4. Customer Analysis – Top 10 companies
6. Cytomegalovirus Retinitis Market Forces
6.1. Drivers
6.2. Constraints
6.3. Challenges
6.4. Porters five force model
6.4.2. Bargaining powers of customers
6.4.4. Rivalry among existing players
7. Cytomegalovirus Retinitis Market -Strategic analysis
7.2. Opportunities analysis
7.3. Product life cycle
7.4. Suppliers and distributors Market Share
8. Cytomegalovirus Retinitis Market – By Drug (Market Size -$Million / $Billion)
8.1. Market Size and Market Share Analysis
8.2. Application Revenue and Trend Research
8.3. Product Segment Analysis
8.3.1. Foscarnet
8.3.2. Ganciclovir
8.3.3. Cidofovir
8.3.4. Fomivirsen
9. Cytomegalovirus Retinitis Market – By Treatment (Market Size -$Million / $Billion)
9.1. Anti-CMV Oral Ganciclovir
9.2. Anti-CMV Intravenous Drug Therapy
9.3. Anti-CMV Intraocular (local)
9.4. Anti-HIV Systemic
9.5. Retinal Detachment Through Vitrectomy
10. Cytomegalovirus Retinitis Market – By Route of Administration (Market Size -$Million / $Billion)
10.1. Systemic
10.2. Ocular
11. Cytomegalovirus Retinitis Market – By Dosage Form (Market Size -$Million / $Billion)
11.1. Capsule
11.2. Implant
11.3. Solution
11.4. Tablet
11.5. Others
12. Cytomegalovirus Retinitis - By Geography (Market Size -$Million / $Billion)
12.1. Cytomegalovirus Retinitis Market - North America Segment Research
12.2. North America Market Research (Million / $Billion)
12.2.1. Segment type Size and Market Size Analysis
12.2.2. Revenue and Trends
12.2.3. Application Revenue and Trends by type of Application
12.2.4. Company Revenue and Product Analysis
12.2.5. North America Product type and Application Market Size
12.2.5.1. U.S.
12.2.5.2. Canada
12.2.5.3. Mexico
12.2.5.4. Rest of North America
12.3. Cytomegalovirus Retinitis - South America Segment Research
12.4. South America Market Research (Market Size -$Million / $Billion)
12.4.5. South America Product type and Application Market Size
12.4.5.1. Brazil
12.4.5.2. Venezuela
12.4.5.3. Argentina
12.4.5.4. Ecuador
12.4.5.5. Peru
12.4.5.6. Colombia
12.4.5.7. Costa Rica
12.4.5.8. Rest of South America
12.5. Cytomegalovirus Retinitis - Europe Segment Research
12.6. Europe Market Research (Market Size -$Million / $Billion)
12.6.5. Europe Segment Product type and Application Market Size
12.6.5.1. U.K
12.6.5.2. Germany
12.6.5.3. Italy
12.6.5.4. France
12.6.5.5. Netherlands
12.6.5.6. Belgium
12.6.5.7. Spain
12.6.5.8. Denmark
12.6.5.9. Rest of Europe
12.7. Cytomegalovirus Retinitis – APAC Segment Research
12.8. APAC Market Research (Market Size -$Million / $Billion)
12.8.5. APAC Segment – Product type and Application Market Size
12.8.5.1. China
12.8.5.2. Australia
12.8.5.3. Japan
12.8.5.4. South Korea
12.8.5.5. India
12.8.5.6. Taiwan
12.8.5.7. Malaysia
13. Cytomegalovirus Retinitis Market - Entropy
13.2. M&A's, collaborations, JVs and partnerships
14. Cytomegalovirus Retinitis Market – Industry / Segment Competition landscape Premium
14.1. Market Share Analysis
14.1.1. Market Share by Country- Top companies
14.1.2. Market Share by Region- Top 10 companies
14.1.3. Market Share by type of Application – Top 10 companies
14.1.4. Market Share by type of Product / Product category- Top 10 companies
14.1.5. Market Share at global level- Top 10 companies
14.1.6. Best Practises for companies
15. Cytomegalovirus Retinitis Market – Key Company List by Country Premium
16. Cytomegalovirus Retinitis Market Company Analysis
16.1. Market Share, Company Revenue, Products, M&A, Developments
16.2. Bausch & Lomb Incorporated
16.3. Valeant Pharmaceuticals International, Inc.
16.4. Luitpold Pharmaceuticals, Inc.
16.5. F. Hoffman La-Roche Ltd.
16.6. Endo Pharmaceuticals, Inc.
16.7. CSL Behring
16.8. Emcure Pharms, Ltd.
16.9. Hospira, Inc.
16.10. Hospira, Inc.
16.11. Gilead Sciences Inc.
16.12. Company 11
16.14. Company 13 and more
17. Cytomegalovirus Retinitis Market -Appendix
18. Cytomegalovirus Retinitis Market -Methodology Premium
18.1.1. Company Expert Interviews
18.1.2. Industry Databases
18.1.3. Associations
18.1.4. Company News
18.1.5. Company Annual Reports
18.1.6. Application Trends
18.1.7. New Products and Product database
18.1.8. Company Transcripts
18.1.9. R&D Trends
18.1.10. Key Opinion Leaders Interviews
18.1.11. Supply and Demand Trends
Table 1: Cytomegalovirus Retinitis Market Overview 2021-2026
Table 2: Cytomegalovirus Retinitis Market Leader Analysis 2018-2019 (US$)
Table 3: Cytomegalovirus Retinitis Market Product Analysis 2018-2019 (US$)
Table 4: Cytomegalovirus Retinitis Market End User Analysis 2018-2019 (US$)
Table 5: Cytomegalovirus Retinitis Market Patent Analysis 2013-2018* (US$)
Table 6: Cytomegalovirus Retinitis Market Financial Analysis 2018-2019 (US$)
Table 7: Cytomegalovirus Retinitis Market Driver Analysis 2018-2019 (US$)
Table 8: Cytomegalovirus Retinitis Market Challenges Analysis 2018-2019 (US$)
Table 9: Cytomegalovirus Retinitis Market Constraint Analysis 2018-2019 (US$)
Table 10: Cytomegalovirus Retinitis Market Supplier Bargaining Power Analysis 2018-2019 (US$)
Table 11: Cytomegalovirus Retinitis Market Buyer Bargaining Power Analysis 2018-2019 (US$)
Table 12: Cytomegalovirus Retinitis Market Threat of Substitutes Analysis 2018-2019 (US$)
Table 13: Cytomegalovirus Retinitis Market Threat of New Entrants Analysis 2018-2019 (US$)
Table 14: Cytomegalovirus Retinitis Market Degree of Competition Analysis 2018-2019 (US$)
Table 15: Cytomegalovirus Retinitis Market Value Chain Analysis 2018-2019 (US$)
Table 16: Cytomegalovirus Retinitis Market Pricing Analysis 2021-2026 (US$)
Table 17: Cytomegalovirus Retinitis Market Opportunities Analysis 2021-2026 (US$)
Table 18: Cytomegalovirus Retinitis Market Product Life Cycle Analysis 2021-2026 (US$)
Table 19: Cytomegalovirus Retinitis Market Supplier Analysis 2018-2019 (US$)
Table 20: Cytomegalovirus Retinitis Market Distributor Analysis 2018-2019 (US$)
Table 21: Cytomegalovirus Retinitis Market Trend Analysis 2018-2019 (US$)
Table 22: Cytomegalovirus Retinitis Market Size 2018 (US$)
Table 23: Cytomegalovirus Retinitis Market Forecast Analysis 2021-2026 (US$)
Table 24: Cytomegalovirus Retinitis Market Sales Forecast Analysis 2021-2026 (Units)
Table 25: Cytomegalovirus Retinitis Market, Revenue & Volume, By Drug, 2021-2026 ($)
Table 26: Cytomegalovirus Retinitis Market By Drug, Revenue & Volume, By Foscarnet, 2021-2026 ($)
Table 27: Cytomegalovirus Retinitis Market By Drug, Revenue & Volume, By Ganciclovir, 2021-2026 ($)
Table 28: Cytomegalovirus Retinitis Market By Drug, Revenue & Volume, By Cidofovir, 2021-2026 ($)
Table 29: Cytomegalovirus Retinitis Market By Drug, Revenue & Volume, By Fomivirsen, 2021-2026 ($)
Table 30: Cytomegalovirus Retinitis Market, Revenue & Volume, By Treatment, 2021-2026 ($)
Table 31: Cytomegalovirus Retinitis Market By Treatment, Revenue & Volume, By Anti-CMV Oral Ganciclovir, 2021-2026 ($)
Table 32: Cytomegalovirus Retinitis Market By Treatment, Revenue & Volume, By Anti-CMV Intravenous Drug Therapy, 2021-2026 ($)
Table 33: Cytomegalovirus Retinitis Market By Treatment, Revenue & Volume, By Anti-CMV Intraocular (local), 2021-2026 ($)
Table 34: Cytomegalovirus Retinitis Market By Treatment, Revenue & Volume, By Anti-HIV Systemic, 2021-2026 ($)
Table 35: Cytomegalovirus Retinitis Market By Treatment, Revenue & Volume, By Retinal Detachment Through Vitrectomy, 2021-2026 ($)
Table 36: Cytomegalovirus Retinitis Market, Revenue & Volume, By Route of Administration, 2021-2026 ($)
Table 37: Cytomegalovirus Retinitis Market By Route of Administration, Revenue & Volume, By Systemic, 2021-2026 ($)
Table 38: Cytomegalovirus Retinitis Market By Route of Administration, Revenue & Volume, By Ocular, 2021-2026 ($)
Table 39: Cytomegalovirus Retinitis Market, Revenue & Volume, By Dosage Form, 2021-2026 ($)
Table 40: Cytomegalovirus Retinitis Market By Dosage Form, Revenue & Volume, By Capsule, 2021-2026 ($)
Table 41: Cytomegalovirus Retinitis Market By Dosage Form, Revenue & Volume, By Implant, 2021-2026 ($)
Table 42: Cytomegalovirus Retinitis Market By Dosage Form, Revenue & Volume, By Solution, 2021-2026 ($)
Table 43: Cytomegalovirus Retinitis Market By Dosage Form, Revenue & Volume, By Table t, 2021-2026 ($)
Table 44: North America Cytomegalovirus Retinitis Market, Revenue & Volume, By Drug, 2021-2026 ($)
Table 45: North America Cytomegalovirus Retinitis Market, Revenue & Volume, By Treatment, 2021-2026 ($)
Table 46: North America Cytomegalovirus Retinitis Market, Revenue & Volume, By Route of Administration, 2021-2026 ($)
Table 47: North America Cytomegalovirus Retinitis Market, Revenue & Volume, By Dosage Form, 2021-2026 ($)
Table 48: South america Cytomegalovirus Retinitis Market, Revenue & Volume, By Drug, 2021-2026 ($)
Table 49: South america Cytomegalovirus Retinitis Market, Revenue & Volume, By Treatment, 2021-2026 ($)
Table 50: South america Cytomegalovirus Retinitis Market, Revenue & Volume, By Route of Administration, 2021-2026 ($)
Table 51: South america Cytomegalovirus Retinitis Market, Revenue & Volume, By Dosage Form, 2021-2026 ($)
Table 52: Europe Cytomegalovirus Retinitis Market, Revenue & Volume, By Drug, 2021-2026 ($)
Table 53: Europe Cytomegalovirus Retinitis Market, Revenue & Volume, By Treatment, 2021-2026 ($)
Table 54: Europe Cytomegalovirus Retinitis Market, Revenue & Volume, By Route of Administration, 2021-2026 ($)
Table 55: Europe Cytomegalovirus Retinitis Market, Revenue & Volume, By Dosage Form, 2021-2026 ($)
Table 56: APAC Cytomegalovirus Retinitis Market, Revenue & Volume, By Drug, 2021-2026 ($)
Table 57: APAC Cytomegalovirus Retinitis Market, Revenue & Volume, By Treatment, 2021-2026 ($)
Table 58: APAC Cytomegalovirus Retinitis Market, Revenue & Volume, By Route of Administration, 2021-2026 ($)
Table 59: APAC Cytomegalovirus Retinitis Market, Revenue & Volume, By Dosage Form, 2021-2026 ($)
Table 60: Middle East & Africa Cytomegalovirus Retinitis Market, Revenue & Volume, By Drug, 2021-2026 ($)
Table 61: Middle East & Africa Cytomegalovirus Retinitis Market, Revenue & Volume, By Treatment, 2021-2026 ($)
Table 62: Middle East & Africa Cytomegalovirus Retinitis Market, Revenue & Volume, By Route of Administration, 2021-2026 ($)
Table 63: Middle East & Africa Cytomegalovirus Retinitis Market, Revenue & Volume, By Dosage Form, 2021-2026 ($)
Table 64: Russia Cytomegalovirus Retinitis Market, Revenue & Volume, By Drug, 2021-2026 ($)
Table 65: Russia Cytomegalovirus Retinitis Market, Revenue & Volume, By Treatment, 2021-2026 ($)
Table 66: Russia Cytomegalovirus Retinitis Market, Revenue & Volume, By Route of Administration, 2021-2026 ($)
Table 67: Russia Cytomegalovirus Retinitis Market, Revenue & Volume, By Dosage Form, 2021-2026 ($)
Table 68: Israel Cytomegalovirus Retinitis Market, Revenue & Volume, By Drug, 2021-2026 ($)
Table 69: Israel Cytomegalovirus Retinitis Market, Revenue & Volume, By Treatment, 2021-2026 ($)
Table 70: Israel Cytomegalovirus Retinitis Market, Revenue & Volume, By Route of Administration, 2021-2026 ($)
Table 71: Israel Cytomegalovirus Retinitis Market, Revenue & Volume, By Dosage Form, 2021-2026 ($)
Table 72: Top Companies 2018 (US$) Cytomegalovirus Retinitis Market, Revenue & Volume
Table 73: Product Launch 2018-2019 Cytomegalovirus Retinitis Market, Revenue & Volume
Table 74: Mergers & Acquistions 2018-2019 Cytomegalovirus Retinitis Market, Revenue & Volume
Figure 1: Overview of Cytomegalovirus Retinitis Market 2021-2026
Figure 2: Market Share Analysis for Cytomegalovirus Retinitis Market 2018 (US$)
Figure 3: Product Comparison in Cytomegalovirus Retinitis Market 2018-2019 (US$)
Figure 4: End User Profile for Cytomegalovirus Retinitis Market 2018-2019 (US$)
Figure 5: Patent Application and Grant in Cytomegalovirus Retinitis Market 2013-2018* (US$)
Figure 6: Top 5 Companies Financial Analysis in Cytomegalovirus Retinitis Market 2018-2019 (US$)
Figure 7: Market Entry Strategy in Cytomegalovirus Retinitis Market 2018-2019
Figure 8: Ecosystem Analysis in Cytomegalovirus Retinitis Market 2018
Figure 9: Average Selling Price in Cytomegalovirus Retinitis Market 2021-2026
Figure 10: Top Opportunites in Cytomegalovirus Retinitis Market 2018-2019
Figure 11: Market Life Cycle Analysis in Cytomegalovirus Retinitis Market
Figure 12: GlobalBy Drug Cytomegalovirus Retinitis Market Revenue, 2021-2026 ($)
Figure 13: GlobalBy Treatment Cytomegalovirus Retinitis Market Revenue, 2021-2026 ($)
Figure 14: GlobalBy Route of Administration Cytomegalovirus Retinitis Market Revenue, 2021-2026 ($)
Figure 15: GlobalBy Dosage Form Cytomegalovirus Retinitis Market Revenue, 2021-2026 ($)
Figure 16: Global Cytomegalovirus Retinitis Market - By Geography
Figure 17: Global Cytomegalovirus Retinitis Market Value & Volume, By Geography, 2021-2026 ($)
Figure 18: Global Cytomegalovirus Retinitis Market CAGR, By Geography, 2021-2026 (%)
Figure 19: North America Cytomegalovirus Retinitis Market Value & Volume, 2021-2026 ($)
Figure 20: US Cytomegalovirus Retinitis Market Value & Volume, 2021-2026 ($)
Figure 24: Canada Cytomegalovirus Retinitis Market Value & Volume, 2021-2026 ($)
Figure 28: Mexico Cytomegalovirus Retinitis Market Value & Volume, 2021-2026 ($)
Figure 32: South America Cytomegalovirus Retinitis Market Value & Volume, 2021-2026 ($)
Figure 33: Brazil Cytomegalovirus Retinitis Market Value & Volume, 2021-2026 ($)
Figure 37: Venezuela Cytomegalovirus Retinitis Market Value & Volume, 2021-2026 ($)
Figure 41: Argentina Cytomegalovirus Retinitis Market Value & Volume, 2021-2026 ($)
Figure 45: Ecuador Cytomegalovirus Retinitis Market Value & Volume, 2021-2026 ($)
Figure 49: Peru Cytomegalovirus Retinitis Market Value & Volume, 2021-2026 ($)
Figure 53: Colombia Cytomegalovirus Retinitis Market Value & Volume, 2021-2026 ($)
Figure 57: Costa Rica Cytomegalovirus Retinitis Market Value & Volume, 2021-2026 ($)
Figure 61: Europe Cytomegalovirus Retinitis Market Value & Volume, 2021-2026 ($)
Figure 62: U.K Cytomegalovirus Retinitis Market Value & Volume, 2021-2026 ($)
Figure 66: Germany Cytomegalovirus Retinitis Market Value & Volume, 2021-2026 ($)
Figure 70: Italy Cytomegalovirus Retinitis Market Value & Volume, 2021-2026 ($)
Figure 74: France Cytomegalovirus Retinitis Market Value & Volume, 2021-2026 ($)
Figure 78: Netherlands Cytomegalovirus Retinitis Market Value & Volume, 2021-2026 ($)
Figure 82: Belgium Cytomegalovirus Retinitis Market Value & Volume, 2021-2026 ($)
Figure 86: Spain Cytomegalovirus Retinitis Market Value & Volume, 2021-2026 ($)
Figure 90: Denmark Cytomegalovirus Retinitis Market Value & Volume, 2021-2026 ($)
Figure 94: APAC Cytomegalovirus Retinitis Market Value & Volume, 2021-2026 ($)
Figure 95: China Cytomegalovirus Retinitis Market Value & Volume, 2021-2026
Figure 98: China Export and Import Value & Volume, 2018-2019 ($) Cytomegalovirus Retinitis Market China Export and Import Value & Volume, 2018-2019 ($)
Figure 99: Australia Cytomegalovirus Retinitis Market Value & Volume, 2021-2026 ($)
Figure 100: Australia GDP and Population, 2018-2019 ($)
Figure 103: South Korea Cytomegalovirus Retinitis Market Value & Volume, 2021-2026 ($)
Figure 107: India Cytomegalovirus Retinitis Market Value & Volume, 2021-2026 ($)
Figure 111: Taiwan Cytomegalovirus Retinitis Market Value & Volume, 2021-2026 ($)
Figure 115: Malaysia Cytomegalovirus Retinitis Market Value & Volume, 2021-2026 ($)
Figure 119: Hong Kong Cytomegalovirus Retinitis Market Value & Volume, 2021-2026 ($)
Figure 123: Middle East & Africa Cytomegalovirus Retinitis Market Middle East & Africa 3D Printing Market Value & Volume, 2021-2026 ($)
Figure 124: Russia Cytomegalovirus Retinitis Market Value & Volume, 2021-2026 ($)
Figure 128: Israel Cytomegalovirus Retinitis Market Value & Volume, 2021-2026 ($)
Figure 132: Entropy Share, By Strategies, 2018-2019* (%) Cytomegalovirus Retinitis Market
Figure 133: Developments, 2018-2019* Cytomegalovirus Retinitis Market
Figure 134: Company 1 Cytomegalovirus Retinitis Market Net Revenue, By Years, 2018-2019* ($)
Figure 135: Company 1 Cytomegalovirus Retinitis Market Net Revenue Share, By Business segments, 2018 (%)
Figure 136: Company 1 Cytomegalovirus Retinitis Market Net Sales Share, By Geography, 2018 (%)
Figure 161: Company 10 Cytomegalovirus Retinitis Market Net Revenue, By Years, 2018-2019* ($)
Figure 162: Company 10 Cytomegalovirus Retinitis Market Net Revenue Share, By Business segments, 2018 (%)
Figure 163: Company 10 Cytomegalovirus Retinitis Market Net Sales Share, By Geography, 2018 (%)